Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma.

[1]  I. Rodger.  Role of leukotrienes and leukotriene receptor antagonist in asthma: new advances. , 1997, Journal of investigational allergology & clinical immunology.

[2]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[3]  J. Kemp,et al.  Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. , 1997, Clinical therapeutics.

[4]  S. Suissa,et al.  Effectiveness of the Leukotriene Receptor Antagonist Zafirlukast for Mild-to-Moderate Asthma , 1997, Annals of Internal Medicine.

[5]  B. Undem,et al.  Cysteinyl leukotrienes in asthma: old mediators up to new tricks. , 1995, Trends in pharmacological sciences.

[6]  M. Johnson.  Pharmacology of long-acting beta-agonists. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  D. Pearlman.  Long-acting beta 2-agonist salmeterol compared with albuterol in maintenance asthma therapy. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[9]  W. Henderson.  The Role of Leukotrienes in Inflammation , 1994, Annals of Internal Medicine.

[10]  S. Spector,et al.  Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. , 1994, American journal of respiratory and critical care medicine.

[11]  Christin Wenzel,et al.  Salmeterol: A Novel, Long-Acting Beta2-Agonist , 1993, The Annals of pharmacotherapy.

[12]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[13]  J. Palmer,et al.  A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. , 1992, The European respiratory journal.

[14]  R. Dahl,et al.  Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. , 1991, The European respiratory journal.

[15]  M. Johnson,et al.  Salmeterol: a potent and long‐acting inhibitor of inflammatory mediator release from human lung , 1991, British journal of pharmacology.

[16]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.

[17]  G. Polgar,et al.  Pulmonary Function Testing in Children: Techniques and Standards , 1977 .